HITPC: More eligible providers attesting to MU Stage 2

As of June, 1,898 eligible professionals (EPs) and 78 eligible hospitals (EHs) have attested to Meaningful Use (MU) Stage 2, according to data presented by Elisabeth Myers, policy and outreach lead at the Centers for Medicare & Medicaid Services, at the Health IT Policy Committee meeting on Aug. 6.

This is a significant increase since last month, when the agency reported that 447 EPs and 8 EHs had attested to MU Stage 2.

In total, 5,365 EPs and 322 EHs attested for the 2014 reporting period. Of these, 955 EPs and 131 EHs are new participants.

In other data presented, 94.95 percent, or 4,741 of 4,993 total EHs, have registered with the agency—signaling an intent to participate in the program. Of these, 4,588 have received MU incentive payments.

Of the total 537,000 EPs, 320,891 Medicare EPs and 159,049 Medicaid EPs have registered with the program. Of these, 264,058 Medicare EPs and 125,778 Medicaid EPs have earned payments.

Myers said that agency actively is seeking comments on its EHR incentive program, and directed stakeholders to provide input at www.cms.gov/ehrincentiveprograms.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.